After abiraterone, 82.2% of men with advanced prostate cancer had no scan-detected progression at six months.
Celcuity Inc. (CELC) reported updated Phase 1b/2 study results for gedatolisib in mCRPC patients. 82.2% of abiraterone-pretreated patients had no progression at six months. Median rPFS was 15.7 months. Phase 2 study expected in 2027.
How this was made
The 30-second read
Why it matters
The data provide the first quantitative efficacy readout for the gedatolisib/darolutamide combo, likely influencing upcoming Phase 2 design and investor sentiment.
Market read
Early trial success could catalyze a short‑term rally in CELC and affect peer biotech valuations.
What to watch
Potential safety concerns and small patient numbers could temper long‑term valuation.
Background
Celcuity (NASDAQ: CELC) presented updated Phase 1b/2 data at ESMO 2026, highlighting rPFS6 rates and PSA responses across dose cohorts.
Ticker impact
Celcuity disclosed Phase 1b/2 trial results for gedatolisib plus darolutamide in mCRPC, showing 82.2% rPFS6 after abiraterone.
likely upward pressure as investors price in potential Phase 2 success.
First disclosure of meaningful efficacy signals in a late‑stage prostate cancer combo; biotech stocks typically react strongly to early trial readouts.
Market effects
May lift other PI3K/mTOR targeted therapy stocks and raise interest in prostate cancer biotech pipelines.
Limited to US biotech sector; no broader regional effect.
Modest, confined to biotech investors worldwide.
Counterpoint
Early‑stage data may not translate to Phase 3 success; caution on over‑optimism.
Key entities
- companyCelcuity Inc.
Biotech firm developing gedatolisib.
- drugDarolutamide
Androgen receptor inhibitor used in the combo.
